bridging science, policy and advocacy
precision medicine
precision medicine and biomarkers present an incredible opportunity to revolutionize health care. it has the potential to change the way we think about, identify and manage cancer care. the impact on both clinical research and patient care will grow as our understanding and technologies improve transforming the delivery of cancer care to benefit both patients and cancer care systems.
managing innovation in oncology
capacity building
the cancer collaborative considers advocacy an important tool in improving cancer care at provincial, national and global levels and patient advocates who are well informed and who have a thorough understanding of the clinical and political landscape can better identify, shape and influence policy and develop effective advocacy strategies and communication with decision makers. strengthening their capacity to address québec specific challenges and opportunities, and to better understand, respond and engage within the pan-canadian environment to proactively engage in an effective and efficient manner.
when to talk to your healthcare team about biomarker testing
because not all tumours behave the same way, biomarkers can provide information about the molecular characteristics of a tumour creating a personalized approach to treating cancer. knowing your biomarker status can determine if targeted therapies are right for you and...
why precision medicine matters
when we talk about mutations, this represents a very small amount of cancer patients - in colorectal cancer for example, mutations in NTRK, MSI-h/dMMR, and BRAF are considered rare [1%, 15%, 9% respectively]. however, this actually represents respectively-...
colorectal cancer canada survey results on molecular profiling in canada
@coloncanada through their GET PERSONAL program launched a two phase project- the first phase of the project included a The first phase of the project included a pan-tumour, pan-canadian survey that was sent to multi-disciplinary healthcare professionals aimed to...
when to talk to your healthcare team about biomarker testing
because not all tumours behave the same way, biomarkers can provide information about the molecular characteristics of a tumour creating a personalized approach to treating cancer. knowing your biomarker status can determine if targeted therapies are right for you and...
why precision medicine matters
when we talk about mutations, this represents a very small amount of cancer patients - in colorectal cancer for example, mutations in NTRK, MSI-h/dMMR, and BRAF are considered rare [1%, 15%, 9% respectively]. however, this actually represents respectively-...
colorectal cancer canada survey results on molecular profiling in canada
@coloncanada through their GET PERSONAL program launched a two phase project- the first phase of the project included a The first phase of the project included a pan-tumour, pan-canadian survey that was sent to multi-disciplinary healthcare professionals aimed to...
let’s talk about biomarkers – BRAF
BRAF represents one of the most frequently mutated protein kinase genes in human tumours. BRAF mutation is seen in melanoma, papillary thyroid carcinoma [including papillary thyroid carcinoma arising from ovarian teratoma], ovarian serous tumours, colorectal...
our REPORTs
Addressing long-term impacts of the pandemic on cancer care /via @globeandmail https://www.theglobeandmail.com/life/adv/article-addressing-long-term-impacts-of-the-pandemic-on-cancer-care/?utm_medium=Referrer:+Social+Network+/+Media&utm_campaign=Shared+Web+Article+Links